News & Updates
Filter by Specialty:
Metformin discontinuation ups cardio-renal events in CKD patients with diabetes
Putting an end to the use of metformin may lead to a higher risk of cardio-renal events in patients with diabetes and advanced chronic kidney disease (CKD), regardless of their cardiovascular disease (CVD) status, suggests a study presented at ADA 2023.
Metformin discontinuation ups cardio-renal events in CKD patients with diabetes
18 Jul 2023
Theophylline shows promise in SCI-induced bradycardia
Use of theophylline as an adjunctive therapy appears to lead to favourable outcomes among patients with bradycardia due to acute spinal cord injury (SCI) with an acceptable response to this agent, suggest the results of a study.
Theophylline shows promise in SCI-induced bradycardia
18 Jul 2023
Phase III data support long-term efficacy of TAF against HBV
Two phase III studies presented at EASL 2023 reflected the long-term efficacy of tenofovir alafenamide (TAF) for individuals with HBeAg*-positive and HBeAg-negative chronic hepatitis B virus (HBV).
Phase III data support long-term efficacy of TAF against HBV
18 Jul 2023
RA remission rates higher with abatacept, certolizumab pegol vs conventional therapy
In the treatment of rheumatoid arthritis (RA), more patients achieve clinical remission with abatacept or certolizumab pegol, but not with tocilizumab, than with active conventional therapy, according to a study.
RA remission rates higher with abatacept, certolizumab pegol vs conventional therapy
17 Jul 2023
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
Treatment with sodium-glucose lowering co-transporter 2 inhibitors (SGLT2i) helps arrest the decline in estimated glomerular filtration rate (eGFR) and is associated with a lower risk of adverse kidney events among adults with diabetes, irrespective of baseline albuminuria status, as shown in a study presented at the recent ADA 2023.
SGLT2 inhibitors tied to kidney benefits, reduced MACE risk
17 Jul 2023
Bezlotoxumab prevents CDI recurrence in immunocompromised patients
Treatment with bezlotoxumab results in a significant decrease in recurrent Clostridioides difficile infection (CDI) in a cohort of immunocompromised patients and transplant recipients, reports a study.